{
    "root": "34663f62-7dff-816a-e063-6394a90a9859",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lamotrigine",
    "value": "20250505",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "LAMOTRIGINE",
            "code": "U3H27498KS"
        }
    ],
    "indications": "Lamotrigine tablets are indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic      seizures. generalized seizures of Lennox-Gastaut      syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older : Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established.",
    "contraindications": "Dosing is based on concomitant medications, indication, and patient age. ( 2.1 , 2.2 , 2.3 , 2.4 ) To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. ( 2.1 ) Do not restart lamotrigine tablets in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. ( 2.1 , 5.1 ) Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing oral contraceptives. ( 2.1 , 5.9 ) Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). ( 2.1 , 5.10 ) Epilepsy : Adjunctive therapy—See Table 1 for      patients older than 12 years and Tables 2 and 3 for patients aged 2 to 12      years. ( 2.2 ) Conversion to monotherapy—See Table      4. ( 2.3 ) Bipolar disorder : See Tables 5 and 6. ( 2.4 )",
    "warningsAndPrecautions": "Lamotrigine Tablets USP, 25 mg\n                  White, caplet shaped, biconvex tablets with 'U' debossed on either side of break line on one side and '111' debossed on other side.\n                  NDC: 70518-1908-00\n                  NDC: 70518-1908-01\n                  NDC: 70518-1908-02\n                  NDC: 70518-1908-03\n                  NDC: 70518-1908-04\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 180 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] in a dry place.\n                  Dispense in tight, light-resistant container as defined in the USP.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Hypersensitivity to the drug or its ingredients. ( Boxed Warning , 4 )"
}